C4 Therapeutics, Inc. Operating Lease Cost
C4 Therapeutics, Inc. (CCCC) reported Operating Lease Cost of $9.75 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-26
- C4 Therapeutics, Inc. operating lease, cost for the quarter ending 2022-12-31 was $2.51M, a 224.03% increase year-over-year.
- C4 Therapeutics, Inc. operating lease, cost for the quarter ending 2022-09-30 was $2.51M, a 293.72% increase year-over-year.
- C4 Therapeutics, Inc. operating lease, cost for the quarter ending 2022-06-30 was $2.51M, a 292.95% increase year-over-year.
- C4 Therapeutics, Inc. operating lease, cost for the quarter ending 2021-12-31 was $774.00K.
- C4 Therapeutics, Inc. operating lease, cost for fiscal 2025 was $9.75M, a 2.82% decline from fiscal 2024.
- C4 Therapeutics, Inc. operating lease, cost for fiscal 2024 was $10.03M, a 0.00% change from fiscal 2023.
- C4 Therapeutics, Inc. operating lease, cost for fiscal 2023 was $10.03M, a 0.01% decline from fiscal 2022.
- C4 Therapeutics, Inc. operating lease, cost for fiscal 2022 was $10.03M, a 273.45% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $9.75M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $10.03M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $10.03M 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $5.02M derived: sum of 2 quarters · filed 2024-02-22 | $7.52M derived: sum of 3 quarters · filed 2024-02-22 | $10.03M 10-K · filed 2024-02-22 |
| 2022-09-30 | $2.51M 10-Q · filed 2022-11-03 | $5.01M derived: sum of 2 quarters · filed 2022-11-03 | $7.52M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $2.51M 10-Q · filed 2022-08-04 | $5.01M 10-Q · filed 2022-08-04 | ||
| 2021-12-31 | $774.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.41M derived: sum of 2 quarters · filed 2023-02-23 | $2.05M derived: sum of 3 quarters · filed 2023-02-23 | $2.69M 10-K · filed 2023-02-23 |
| 2021-09-30 | $637.00K 10-Q · filed 2022-11-03 | $1.27M derived: sum of 2 quarters · filed 2022-11-03 | $1.91M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $638.00K 10-Q · filed 2022-08-04 | $1.27M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |